Eli Lilly and Company

(New York Stock Exchange)

Top News rankings and signal summaries are processed using AI and may contain errors.

21
Bullish +65

Abbisko Therapeutics enters potential $1.9 billion R&D deal with Eli Lilly

AI-generated analysis

Eli Lilly has entered into a new collaboration agreement with Abbisko Therapeutics, a subsidiary of oncology specialist Abbisko Cayman, to jointly discover, develop, and potentially commercialize experimental medicines across multiple targets. The partnership focuses on early-stage drug programs aimed at accelerating the advancement of innovative...

Bullish Signals

  • Abbisko secures up to $1.9 billion in milestone payments from Eli Lilly.
  • Eli Lilly partnership validates R&D capabilities and provides substantial capital resources.
22
Bullish +55

What Has Changed About Owning Eli Lilly Stock?

Capacity expansion Company update AI-generated analysis

Eli Lilly (LLY) has shifted its capital allocation strategy, marking a historic change where capital spending on factories and equipment exceeded research and development for the first time since at least 2011. Over the twelve months ended September 30, 2026, the company spent $19.0 billion...

Bullish Signals

  • Mounjaro/Zepbound revenue exceeded $16B in Q3.
  • Net debt is only 3.9% of market value.
  • Full-year free cash flow reached $11.7B.
  • Ten new U.S. manufacturing sites announced.

Bearish Signals

  • Capex of $19B exceeded R&D of $15.4B, ending 59-quarter streak.
  • Free cash flow dropped to $4.16B in Q3 from $6.03B.
  • Net debt rose to $44.6B by Sep 2026.
23
Bullish +65

Can Eli Lilly’s Growth Keep Justifying its Premium?

Drug pricing Earnings report Guidance raised AI-generated analysis

Eli Lilly and Company (NYSE:LLY) has delivered exceptional growth, with its stock returning over 55% in the past year compared to a 14% gain for the S&P 500. This premium valuation is driven by substantial expectations for future profitability, particularly from its diabetes and obesity...

Bullish Signals

  • Stock returned 55% in past 12 months.
  • Q2 revenue surged 48% to $23.0 billion.
  • Non-GAAP EPS rose 33% to $8.38.
  • Gross margins improved to 86.3%.
  • Raised full-year guidance to $85B-$87B.

Bearish Signals

  • Realized prices dropped 13% domestically, 36% internationally.
  • China's reimbursement list pressured international revenue.
  • Acquisition R&D charges of $3.03/share offset EPS growth.
24
Bearish -65

Pennsylvania sues Eli Lilly, CVS Caremark, and others, alleging insulin ...

Lawsuit AI-generated analysis

Pennsylvania Attorney General Dave Sunday has filed a lawsuit against Eli Lilly and Company, along with Novo Nordisk Inc., Sanofi-Aventis US LLC, and major pharmacy benefit managers including CVS Caremark. The state alleges that these entities conspired to artificially inflate insulin prices, driving costs to...

Bearish Signals

  • Named in PA lawsuit alleging insulin price conspiracy.
  • State claims coordinated conduct raised prices 10x.
  • Lawsuit alleges prioritizing profits over patient access.
  • PA seeks injunctive relief to change pricing.
25
Bullish +62

Eli Lilly (LLY) Stock Forecast & Price Target (2026)

Analyst upgrade AI-generated analysis

As of October 16, 2026, Eli Lilly and Company (LLY) trades at $1,251.61 with a market capitalization of $1.12 trillion. The stock exhibits bullish technical momentum, trading above its 50-day simple moving average of $1,179.04 and showing an RSI of 68, which indicates strength without...

Bullish Signals

  • Trades above moving averages with RSI of 68.

Bearish Signals

  • Lilly Endowment reduced stake to 99% of insider selling.
  • Insiders sold $3.9B vs $4.5M bought over 18 months.